News Sentiment

NMRA sentiment intelligence

Neumora Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.68 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+0.6% over one week, -5.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Neumora Therapeutics Is Maintained at Outperform by RBC Capital

Market Reaction

Balanced read

50/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction 0.6% Price digesting
Trend fit Trend inactive -5.6% over four weeks
Fair value -75.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 26
Negative 15

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
TradingView 7
www.marketscreener.com 5
marketscreener.com 4
Moomoo 3
simplywall.st 3
Timothy Sykes 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 10
Analyst action 9
Regulatory and legal 4
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
Medical Marketing and Media Direct company coverage

Rx Rundown: Sanofi, Neumora Therapeutics, Uniqure and more

This "Rx Rundown" article summarizes recent medical marketing news, deal-making, and industry chatter. It covers significant deals and collaborations involving companies like Eli Lilly, Jazz Pharmaceuticals, and Nvidia, alongside FDA approvals and decisions concerning drugs from

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 12:00
Source
Medical Marketing and Media
Morningstar Direct company coverage

NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations

SueWallSt has initiated an investigation into Neumora Therapeutics (NASDAQ: NMRA) for potential securities law violations after the company's navacaprant program failed two additional Phase 3 trials and was discontinued, leading to a significant drop in share price. The investiga

Tone
Neutral 50/100
Event
Regulatory and legal
Published
17 Jun 2026 13:07
Source
Morningstar